CN102670759A - Traditional Chinese medicine composition for treating atherosclerosis - Google Patents
Traditional Chinese medicine composition for treating atherosclerosis Download PDFInfo
- Publication number
- CN102670759A CN102670759A CN2012101570215A CN201210157021A CN102670759A CN 102670759 A CN102670759 A CN 102670759A CN 2012101570215 A CN2012101570215 A CN 2012101570215A CN 201210157021 A CN201210157021 A CN 201210157021A CN 102670759 A CN102670759 A CN 102670759A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a traditional Chinese medicine composition for treating atherosclerosis. The traditional Chinese medicine composition is mainly prepared from the following raw material medicines in parts by weight or the extracts of the active ingredients thereof: 10-40 parts of paniculate swallowwort root, 10-40 parts of radix clematidis and 10-40 parts of codonopsis pilosula. The traditional Chinese medicine composition disclosed by the invention has a better effect on treating cardiovascular and cerebrovascular arteriosclerosis.
Description
Technical field
The present invention relates to the atherosclerotic medicine of a kind of treatment, particularly relate to the atherosclerotic Chinese medicine composition of a kind of treatment.
Background technology
Atherosclerosis (atherosclerosis) is one group and is called in the arteriosclerotic angiopathy the most common, most important a kind of.Various arteriosclerotic common features are that ductus arteriosus wall thickens hardening, follows the string and tube chamber dwindles.Because the lipid outward appearance of gathering at endarterium is yellow medicated porridge appearance, therefore be called atherosclerosis.At present, atherosclerosis has become " the No.1 killer " who threatens Chinese city and urban residents' life and health.And aging and quickening of urbanization process, problem such as physical exertion minimizing and dietary structure are unreasonable is serious day by day, and the present atherosclerotic of China is up to 6,000 ten thousand people.And along with the improving constantly of living standard, its sickness rate is also constantly increasing progressively, and it is common complaint among the elderly still not, is also approaching youngster gradually.
Previously think that atherosclerosis is a progressive development of linear process, charge into tube chamber, cause luminal stenosis and tissue ischemia, finally cause the generation of acute cardiovascular and cerebrovascular vessel incident because deposition, the speckle under the endarterium of lipid increase gradually.Recent study finds that acute coronary syndrome (ACS) pilosity is born in that coronary artery is light, the patient of moderate stenosis; Causing the main cause of the sick incident of acute cardiovascular is that atheromatous plaque breaks and thrombosis, and the latter is depended on the vulnerability (vulnerablity) of speckle.Atheromatous plaque relates to a plurality of links such as inflammation, immunity, metabolism, blood coagulation from the stable process that becomes rapid wear, and wherein inflammatory reaction is to cause the unsettled key factor of speckle.Though make a breakthrough aspect the speckle vulnerability improving at present, the especially clinical practice of statins and thiophene chloropyridine class medicine still has a lot of problems to need further further investigation.And still do not improve the ideal medicament of speckle vulnerability at present.Actively inquire into the atherosclerotic medicine of treatment, the medicine that particularly improves the speckle vulnerability comprises that the prevention and treatment in Chinese and western strategy still is of great importance.
The acute cardiovascular event morbidity that atherosclerosis causes is hurried, and clinical manifestation is changeful, similar middle style of work card; Its sick position is at heart network, the cause of disease be invade in the wind and cold, improper diet, disorder of emotion and aged debility etc.We pass through the clinical research in year surplus in the of 10 and find that the fundamental mechanism that the atherosclerosis cardiovascular event takes place comprises two aspects of deficiency and excess: real person, malicious, the pyretic toxicity wind-transformation of turbid, the strongly fragrant rotten one-tenth of blood stasis expectorant; Void person; Pathogen usually intruding into collateral in protracted disease, venation are lost and are supported, the network wind syndrome caused by deficiency is moving; The wind of wind of this transconversion into heat or network void has intrinsic concordance with atherosclerosis vulnerable plaque rupture process, is referred to as " network wind "; Propose atherosclerosis " moving network wind in " theory at academia in view of the above, moving in the network wind is the basic pathogenesis of cardiovascular event generation such as acute coronary artery syndrome.
Summary of the invention
The inventor is a theoretical basis with acute coronary syndrome " moving in the network wind " theory.Through long-term lots of clinical practice, the compositions of finding some Chinese medicines and effective ingredient thereof to atherosclerosis, particularly improve speckle vulnerability aspect and show remarkable curative effect, and can reduce the side effect of Western medicine.The inventor is entitled as the medicine of treating coronary heart disease and is coated with on the basis of patent of invention 200810132903.X of coronary artery coating bracket of this medicine the inventor's, constantly brings forth new ideas, perfect.Provide a kind of treatment atherosclerotic Chinese medicine composition at this, said Chinese medicine composition is mainly processed by the crude drug of weight components or the extract of its effective ingredient:
Radix Cynanchi Paniculati 10-40 part,
Radix Clematidis 10-40 part,
Radix Codonopsis 10-40 part.
This acute coronary syndrome that proposes to the inventor " moving in the network wind " theory designs.In the control strategy of coronary atherosclerotic heart disease, when stressing the benefiting QI for activating blood circulation blood stasis dispelling, should consider to use " wind medicine ".Moving in the network wind, when with benefiting QI for activating blood circulation, dispelling wind and removing obstruction in the collateral.The present invention is a monarch drug with the Radix Clematidis of the Radix Cynanchi Paniculati of dispelling wind and removing obstruction in the collateral, blood circulation promoting and blood stasis dispelling and expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, Radix Cynanchi Paniculati and Radix Clematidis be used in combination the effect that has strengthened dispelling wind and removing obstruction in the collateral; Being aided with the Radix Codonopsis with invigorating the spleen and replenishing QI simultaneously is ministerial drug.
Radix Cynanchi Paniculati is the dry root and rhizome of asclepiadaceae plant Radix Cynanchi Paniculati (Cynanchum paniculatum (Bge.) Kitag).Acrid in the mouth, warm in nature; Dispelling wind is analgesic, promoting flow of QI and blood.The rabbit experiment property hyperlipidemia and the experimental atherosclerosis model that cause for the feed cholesterol diet; Radix Cynanchi Paniculati has the effect that reduces serum total cholesterol and beta lipoprotein; And can alleviate atherosclerosis of aorta and small artery lipid deposition, thereby show that Radix Cynanchi Paniculati has preventive and therapeutic effect to atherosclerosis.Usual amounts 3-9g, for oral administration, fry in shallow oil soup.The effective ingredient of Radix Cynanchi Paniculati is mainly paeonol and polysaccharide, and paeonol is a main active.
The effect that Radix Clematidis has wind-damp dispelling, the meridian dredging, the bone that disappears is choked.Many new purposes have been found in modern times in the clinical practice, like treatment cholelithiasis, calcanean spur, talalgia, the esophageal carcinoma etc.But it is noted that the careful clothes of deficiency of qi and blood and anemia of pregnant woman in the medication.
Radix Codonopsis has invigorating the spleen and replenishing QI, the effect of spleen invigorating lung benefiting.Be used for deficiency of the spleen and lung, the cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency cough, interior-heat is quenched one's thirst etc.The Radix Codonopsis QI invigorating, effect is rapid, and the effect of supplementing QI for promoting the production of body fluid is arranged.
Preferably, said Chinese medicine composition also comprises the crude drug of weight components or the extract of its effective ingredient:
Radix Astragali l0-40 part,
Radix Notoginseng 2-10 part,
Lignum Dalbergiae Odoriferae oil 2-10 part.
The Radix Codonopsis QI invigorating can only the spleen invigorating QI invigorating, the power of no consolidating superficial resistance.So be used in combination have invigorating QI to consolidate the body surface resistance, the Radix Astragali of effects such as diuretic detumescent, expelling pus and toxin by strengthening QI, granulation promoting, strengthen the effect of QI invigorating.
The hemostasis of Radix Notoginseng dissipating blood stasis, subduing swelling and relieving pain.Be used for various inside and outside hemorrhage, breast ventral spine pain, tumbling and swelling.Radix Notoginseng has good hemostasia effect, significant hemopoietic function; Can tighten and improve the arteria coronaria microcirculation.
Lignum Dalbergiae Odoriferae oil is to be refined by leguminous plant Lignum Dalbergiae Odoriferae wingceltis to form, and its chemical constituent contains volatile oil, and main constituent has β-heerabolene, trans-β-farnesene, trans-nerolidol etc. in the oil.Nature and flavor temperature, hot has promoting flow of QI and blood, pain relieving, and the hemostatic effect cures mainly diseases such as epigastric pain, hypochondriac pain due to stagnation of liverQI, thoracic obstruction twinge, injury from falling down, traumatic hemorrhage.
Preferably, said Chinese medicine composition is processed by the crude drug of weight components or the extract of its effective ingredient:
20 parts of Radix Cynanchi Paniculatis,
20 parts of Radix Clematidis,
20 parts of Radix Codonopsis
20 parts of the Radixs Astragali,
5 parts of Radix Notoginseng,
5 parts of Lignum Dalbergiae Odoriferae oils.
The dosage form of the atherosclerotic said Chinese medicine composition of treatment provided by the invention is a said dosage form on any pharmaceutics.
Preferably, the dosage form of said Chinese medicine composition is drop pill, tablet or capsule.
Therefore, to can the better healing atherosclerosis, particularly improve the Chinese medicine of speckle vulnerability and the compositions of effective ingredient thereof and exist huge clinical demand.Through clinical trial, for cerebrovascular atherosclerosis therapeutical effect is preferably arranged all according to Chinese medicine composition of the present invention.
The specific embodiment
Below further set forth the beneficial effect of Chinese medicine composition according to the invention through Test Example.
Embodiment 1: 40 parts of Radix Cynanchi Paniculatis, and 10 parts of Radix Clematidis, 20 parts of Radix Codonopsis,
Embodiment 2: 10 parts of Radix Cynanchi Paniculatis, and 40 parts of Radix Clematidis, 20 parts of Radix Codonopsis, 20 parts of the Radixs Astragali, 5 parts of Radix Notoginseng, 5 parts of Lignum Dalbergiae Odoriferae oils,
Embodiment 3: 20 parts of Radix Cynanchi Paniculatis, and 20 parts of Radix Clematidis, 20 parts of Radix Codonopsis, 20 parts of the Radixs Astragali, 5 parts of Radix Notoginseng, 5 parts of Lignum Dalbergiae Odoriferae oils,
Add proper quantity of medicinal auxiliary material, the foregoing description 1,2,3 is prepared as decoction, granule successively; Be prepared as tablet, capsule and drop pill after decoction concentrated.
Test Example 1: the clinical research of treatment unstable angina pectoris
The influence of the granule of embodiment 3 to UA patients serum c reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha inflammatory mediator levels such as (TNF-α) observed in this research, estimates the clinical efficacy of the granule treatment UA of embodiment 3.
Data and method
1. object of study
Patient's 90 examples of selected in March, 2010～2012 year Beijing in March Dongzhimen hospital unstable angina pectoris extract envelope and are divided into conventional therapy group (conventional group, 30 examples), treatment group of the present invention (granule of embodiment 3,30 examples) and Tongxinluo group (30 example) at random.Inclusion criteria: (1) age≤75 year old; (2) meet the unstable angina pectoris diagnostic criteria: the tranquillization angina pectoris (usually the persistent period＞20min), the angina pectoris that takes place recently is [in 2 months; Canada's angina pectoris classification (CCS classification) more than the II level], the angina pectoris that increases the weight of in the recent period (in 2 months, CCS classification II level is above or increase more than 1 grade); (3) signed Informed Consent Form.Exclusion standard: (1) cardiogenic shock; (2) severe heart failure (NYHA cardiac functional grading III～IV level); (3) severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation and asystole etc.); (4) heating, acute or chronic infection, malignant tumor and connective tissue disease etc. are with the disease of inflammatory reaction; (5) experience wound, operation or other serious diseases in the recent period and the present situation that still is in stress state; (6) severe hepatic renal damage; (7) use the medicine (like NSAID and steroid etc.) that suppresses inflammatory reaction.
Physical data: conventional group 30 examples, male's 19 examples, the age is at 46～72 years old, and average 60.6 ± 8.9 years old, the course of disease was in 1～8 year, and average 5.16 ± 1.32 years, smoker's 5 examples wherein, complication with diabetes 4 examples, hypertension 8 examples, hyperlipemia 12 examples.30 examples are organized in treatment of the present invention, male's 20 examples, and the age, average 66.0 ± 9.4 years old, the course of disease was 2～7 years at 45～77 years old, average 5.48 ± 1.51 years, smoker's 10 examples, complication with diabetes 6 examples, hypertension 15 examples, hyperlipemia 14 examples.Tongxinluo group 30 examples, male's 13 examples, the age, average 62.6 ± 8.8 years old, the course of disease was 1～9 year at 44～78 years old, average 5.05 ± 1.77 years, smoker l0 example, complication with diabetes 6 examples, hypertension 15 examples, hyperlipemia 11 examples.Two groups of aspects such as patient age, sex, the course of disease and coronary risk factor similar (P>0.05).
2. method
2.1 administrated method
Each organize amphibolia all lie up, oxygen uptake, cardiac monitoring.Quiet nitroglycerin 5mg of conventional group, 1/ day, oral sorbitrate l0mg, 3/ day, metoprolol 25mg, 2/ day visits aspirin 100mg, 1/ day, subcutaneous injection Low molecular heparin 0.1mg/Kg, 2/ day, be 2 weeks the course of treatment.Two groups of backs added granule with embodiment 3 (by Dongzhimen Hospital, Beijing Univ of Traditional Chinese Medicine's preparation) 6g, 3/ day and TONGXINLUO JIAONANG (Yiling Pharmaceutical Co., Ltd, Shijiazhuang's production, lot number 19981527) respectively 4,3/ day, were for 2 weeks the course of treatment.Merge the oral simvastatin 20mg of hyperlipemia, 1/ evening; The oral captopril 25mg of complicated hypertension, 3/ day add Norvasc 5mg, 1/ day if can not control; The oral glucobay (acarbose) 50mg of complication with diabetes, 3/ day, with the 1st mouthful of meal with clothes.
2.2 observation index
(1) angina pectoris symptom curative effect, electrocardiogram improvement rate; (2) routine blood test (automatic blood cell analysis-e/or determining), hepatic and renal function (automatic clinical chemistry analyzer mensuration), blood-fat and blood sugar (automatic clinical chemistry analyzer mensuration), myocardium enzyme (automatic clinical chemistry analyzer mensuration) and Troponin I (semiquantitative method); (3) plasma C RP, IL-6, TNF-alpha levels.
2.3 the blood plasma inflammatory mediator is measured
All patients are all preceding in taking medicine, the ulnar vein blood specimen is gathered 2 early mornings in week on an empty stomach in the back of taking medicine, and adopt laser light scattering turbidimetry for Determination CRP, enzyme linked immunosorbent assay (ELISA) to measure IL-6, TNF-alpha levels.Detecting required test kit is provided by the rich biological preparation company limited of fitting in Shanghai, and These parameters is hospital's collect specimen and measuring in Dongzhimen, Beijing.
2.4 efficacy assessment standard
Angina pectoris symptom efficacy assessment standard and ECG curative effect evaluation criteria reference literature.Symptom curative effect determinate standard: (1) produce effects: transference cure or basic the disappearance; (2) effective: pain attack times, degree and persistent period obviously alleviate; (3) invalid: symptom basic with treat before identical.ECG curative effect criterion: (1) produce effects: electrocardiogram returns to " roughly normal "; (2) effective: more than the treatment back ST section rise 0.05mv, but do not reach normal level, shoal (reaching more than 25%) at the negative T wave that mainly leads, perhaps the T ripple becomes uprightly chamber or intraventricular block improver by smooth; (3) invalid: electrocardiogram basic with treat before identical.
2.5 statistical analysis
Use the SPSS11.0 statistical software.Measurement data representes that with mean ± standard deviation enumeration data relatively adopts the independent sample t check with frequency (frequency) expression before and after the group internal therapy, relatively adopt one factor analysis of variance between group, and P≤0.05 is thought has statistical significance.
The result
1. respectively organize patient's angina pectoris symptom curative effect
Each organizes patient's angina pectoris symptom curative effect comparative result: treatment group produce effects 40.5% of the present invention, and effective 52.0%, invalid 7.5%, total effective rate 93.8%; Tongxinluo group produce effects 32.0%, effective 48.7%, invalid 20.3%, total effective rate 76.9%; Conventional group produce effects 20.1%, effective 53.0%, invalid 27.2%, total effective rate 73.8%.The symptom of treatment group of the present invention is evident in efficacy to be higher than conventional therapy group and Tongxinluo group (P < 0.05), there was no significant difference between two groups (P>0.05) then, and the granule of prompting embodiment 3 is superior to TONGXINLUO JIAONANG aspect antianginal.
2. respectively organize patient's ECG curative effect
Each organizes patient's ECG curative effect relatively: treatment group produce effects 33.7% of the present invention, and effective 40.0%, invalid 27.3%, total effective rate 73.6%; Tongxinluo group produce effects 23.2%, effective 37.7%, invalid 40.5%, total effective rate 60.9%; Conventional group produce effects 20.4%, effective 46.0%, invalid 34.5%, total effective rate 66.8%.Electrocardiographic improvement rate is there was no significant difference (P>0.05) between three groups of treatment group of the present invention, Tongxinluo group and conventional groups.
3. respectively organize the comparison of plasma C RP, IL-6, TNF-α and MCR-1 level
The blood plasma inflammatory mediator changes before and after each group treatment of table 1
Annotate: * treats the back relatively with conventional group and Tongxinluo group, and R < 0.05
Levels such as plasma C RR, IL-6, TNF-α all are significantly higher than normal control group (P value all < 0.05) before each group treatment, point out UA patient blood plasma inflammatory mediator level higher.Conventional group and Tongxinluo group inflammation index before and after treatment do not have the significance change (P>0.05; P>0.05), with before the treatment relatively, the equal significance of treatment group treatment back inflammatory mediator level of the present invention reduces (P < 0.05); And significantly be lower than conventional group and the treatment of Tongxinluo group afterwards (P 0.05, P 0.05).
According to embodiments of the invention are Chinese medicinal granule electuaries of the treatment angina pectoris of development under atherosclerosis " moving in the network wind " theory instructs, and Preliminary Applications is in the clinical better effects that obtains.This research is inquired into the clinical effectiveness according to embodiments of the invention treatment unstable angina pectoris from the angle of inflammatory mediator.
Confirmed that it is a marker of inflammation that CRP does not weigh, and be a thrombotic medium of atherosclerosis.Unstable angina pectoris patient's CRP is higher than stable patient with angina pectoris, and the CRP of myocardial infarction is higher than the unstable angina pectoris patient.CRP can combine to make under it deposits in speckle with OxLDL ELISA (LDL) specificity; As patient Gao Min CRP (hs-CRP)>3mg/L time prompting prognosis mala, unstable angina pectoris develops into the patient 90%CRP of acute myocardial infarction (AMI)>3mg/L.Interleukin relates to (IL) and a plurality of inflammatory process relevant with ACS; IL-1 and IL-6 are two kinds of proinflammatory factor prototypes; The former impels the latter to produce, and the latter is outstanding in the early stage effect of local inflammation, can stimulate B and T lymphocyte; Induce Fibrinogen synthetic, and be the primary initiation factor that hepatocyte CRP expresses.In the unstable angina pectoris patient, the IL-6 serum levels raises relevant with prognosis mala, even after the horizontal promoting or transferring of plasma C RP is whole, is still an independent hazard factor.The main component of speckle fibrous cap is an extracellular matrix, comprises collagen fiber and elastin laminin, the mainly synthetic and secretion by VSMC.VSMC synthetic cell epimatrix reduces and/or the increase of protein resolvase degradation of cell epimatrix is the main immanent cause of plaque rupture, and matrix metalloproteinase (MMPs) plays a significant role the latter.Tumor necrosis factor TNF-alpha can stimulate macrophage generation inactive metal protease in the speckle, and this enzyme can become reactive metal protease by plasmin activation in the tissue.Our result of study shows, 90 routine UA patients plasma C RP, IL-6, TNF-α, MCP-1 level before treatment all are significantly higher than matched group (P < 0.05), and this is consistent with bibliographical information.
To the inflammatory process among the ACS; In the middle of the control of coronary heart disease, possibly strengthen the anti-inflammatory strategy; We " move " embodiments of the invention of researching and developing under the theory guidance of accordinging in atherosclerosis in the network wind; Its main component is a paeonol, and pharmacological research confirms that paeonol has significant anti-inflammatory effect.This result of study shows; Conventional group and Tongxinluo group inflammation index before and after treatment does not have significance and changes; Network wind rather organize plasma C RP (9.32 ± 2.67 to 4.69 ± 1.02, P=0.015), IL-6 (20.47 ± 8.85 to 9.72 ± 2.79, P=0.038), TNF-α (39.12 ± 10.41 to 24.45 ± 7.55; P=0.042) all significance reductions before and after treatment; And significantly be lower than conventional group and Tongxinluo group (P 0.05, P 0.05), prompting accordings to embodiments of the invention and has tangible anti-inflammatory effect.Through observation of curative effect to the peaceful allevating angina pectoris symptom of network wind, find that network wind rather organizes total effective rate 93.8%, be significantly higher than Tongxinluo group and conventional group (P 0.05, P 0.05), show according to embodiments of the invention aspect antianginal, to be superior to TONGXINLUO JIAONANG.
The clinical research of Test Example 2 treatment cerebral arteriosclerosis
The clinical efficacy of the drop pill of embodiment 2 to cerebral arteriosclerosis observed in this research.
Patient's 90 examples of selected in March, 2010～2012 year Beijing in March Dongzhimen hospital cerebral arteriosclerosis extract envelope and are divided into conventional therapy group (conventional group, 30 examples), treatment group of the present invention (drop pill of embodiment 2,30 examples) and cinnarizine group (30 example) at random.Patient's readme has following symptom, and brains is uncomfortable; It is bad to sleep; Nearly hypomnesis; Comprehensive judgement descends; Emotion is unusual.As criterion, evidence is superior to cinnarizine according to embodiments of the invention to the therapeutic effect of treating cerebral arteriosclerosis with sx degree before and after taking medicine.Proof all has therapeutical effect preferably according to Chinese medicine composition of the present invention for cerebrovascular atherosclerosis.
Although embodiment of the present invention is open as above; But its not authority listed utilization in description and embodiment; It can be applied to various suitable the field of the invention fully, for being familiar with those skilled in the art, can easily realize other modification; Therefore under the general concept that does not deviate from claim and equivalency range and limited, the instance that the present invention is not limited to specific details and illustrates here and describe.
Claims (5)
1. treat atherosclerotic Chinese medicine composition for one kind, it is characterized in that said Chinese medicine composition is mainly processed by the crude drug of weight components or the extract of its effective ingredient:
10-40 parts of Radix Cynanchi Paniculatis,
10-40 parts of Radix Clematidis,
10-40 parts of Radix Codonopsis.
2. Chinese medicine composition according to claim 1 is characterized in that said Chinese medicine composition also comprises the crude drug of weight components or the extract of its effective ingredient:
10-40 parts of the Radixs Astragali,
2-10 parts of Radix Notoginseng,
Lignum Dalbergiae Odoriferae oil 2-10 part.
3. Chinese medicine composition according to claim 2 is characterized in that said Chinese medicine composition processed by the crude drug of weight components or the extract of its effective ingredient:
20 parts of Radix Cynanchi Paniculatis,
20 parts of Radix Clematidis,
20 parts of Radix Codonopsis
20 parts of the Radixs Astragali,
5 parts of Radix Notoginseng,
5 parts of Lignum Dalbergiae Odoriferae oils.
4. according to arbitrary described Chinese medicine composition among the claim 1-3, the dosage form that it is characterized in that said Chinese medicine composition is a said dosage form on any pharmaceutics.
5. Chinese medicine composition according to claim 4, the dosage form that it is characterized in that said Chinese medicine composition is drop pill, tablet or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101570215A CN102670759A (en) | 2012-05-18 | 2012-05-18 | Traditional Chinese medicine composition for treating atherosclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101570215A CN102670759A (en) | 2012-05-18 | 2012-05-18 | Traditional Chinese medicine composition for treating atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102670759A true CN102670759A (en) | 2012-09-19 |
Family
ID=46803745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101570215A Pending CN102670759A (en) | 2012-05-18 | 2012-05-18 | Traditional Chinese medicine composition for treating atherosclerosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670759A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375316A (en) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process |
| WO2003000242A2 (en) * | 2001-06-25 | 2003-01-03 | Sky Biohealth Solutions, Inc. | Method for the treatment of lymphedema using guaifenesin |
| CN1579443A (en) * | 2003-08-01 | 2005-02-16 | 叶立新 | Medicine for treating deaf-mutism |
| CN1600319A (en) * | 2003-09-23 | 2005-03-30 | 天津天士力制药股份有限公司 | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases |
| CN1692939A (en) * | 2005-04-09 | 2005-11-09 | 滕立刚 | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method |
| WO2012000425A1 (en) * | 2010-06-28 | 2012-01-05 | 天津天士力制药股份有限公司 | Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
-
2012
- 2012-05-18 CN CN2012101570215A patent/CN102670759A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000242A2 (en) * | 2001-06-25 | 2003-01-03 | Sky Biohealth Solutions, Inc. | Method for the treatment of lymphedema using guaifenesin |
| CN1375316A (en) * | 2002-02-07 | 2002-10-23 | 天津天士力制药股份有限公司 | Chinese medicine prepn. for treating coronary heart disease and angina pactoris and its prepn. process |
| CN1579443A (en) * | 2003-08-01 | 2005-02-16 | 叶立新 | Medicine for treating deaf-mutism |
| CN1600319A (en) * | 2003-09-23 | 2005-03-30 | 天津天士力制药股份有限公司 | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases |
| CN1692939A (en) * | 2005-04-09 | 2005-11-09 | 滕立刚 | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method |
| WO2012000425A1 (en) * | 2010-06-28 | 2012-01-05 | 天津天士力制药股份有限公司 | Use of a chinese medicine composition in preparing medicaments for treating secondary prevention of myocardial infarction |
Non-Patent Citations (3)
| Title |
|---|
| 《2011年中华中医药学会心病分会学术年会暨北京中医药学会心血管病专业委员会年会论文集》 20111210 王显 动脉粥样硬化"络风内动"假说与心血管事件链 第9-13页，第12页第2段 2-3、5 , * |
| 无: "北京中医药大学东直门医院心脏中心近期获得国家发明专利", 《HTTP://WWW.DZMYY.COM.CN/NEWS/ARTICLES/INDEX/4415》, 7 April 2011 (2011-04-07), pages 2 - 3 * |
| 王显: "动脉粥样硬化"络风内动"假说与心血管事件链", 《2011年中华中医药学会心病分会学术年会暨北京中医药学会心血管病专业委员会年会论文集》, 10 December 2011 (2011-12-10) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512521A (en) | Traditional Chinese medicine composition for treating apoplexy sequela | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN104147345B (en) | A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy | |
| He et al. | Network pharmacology unveils spleen-fortifying effect of Codonopsis Radix on different gastric diseases based on theory of “same treatment for different diseases” in traditional Chinese medicine | |
| CN102670759A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN102293842A (en) | Preparation for treating ulcerative colitis and preparation method thereof | |
| CN103330796B (en) | A kind of pharmaceutical composition for the treatment of Cardiorenal syndrome | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN103920076A (en) | Traditional Chinese medicine for treating tinea of feet and hands as well as eczema | |
| CN101297827B (en) | Medicament for curing coronary disease and coronary artery coating bracket coated therewith | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN104547522B (en) | A kind of Chinese medicine composition for treating arrhythmia cordis and its application | |
| CN104095843A (en) | Application of arctigenin in preparation of drugs for treatment of digestive tract ulcerative diseases | |
| CN112717021B (en) | Traditional Chinese medicine composition for treating middle and later congestive heart failure and preparation method and application thereof | |
| CN110934980B (en) | Traditional Chinese medicine formula and application thereof | |
| CN102357125B (en) | Chinese herbal medicine composition for treating early occlusive peripheral atherosclerosis | |
| CN104127515B (en) | A kind of compositions treating cerebral thrombotic infarction and preparation method thereof | |
| CN107362275B (en) | Chinese herbal medicine composition for preventing and treating atherosclerosis and preparation method thereof | |
| CN101301384A (en) | Chinese medicinal composition for treating arteriosclerosis | |
| CN1695683A (en) | Oral disintegration tablet prepared from general saponin of notoginseng for treating thrombosis, and preparing technique | |
| CN104721581A (en) | Traditional Chinese medicine composition for treating ischemic heart and cerebral vessel disease and preparation method of traditional Chinese medicine composition | |
| CN112546157A (en) | Traditional Chinese medicine for comprehensively treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN100381134C (en) | Application of pharmaceutical composition in the process for preparing medicine to treat aspirin resistance | |
| CN117205280A (en) | Medicine for treating acute upper gastrointestinal hemorrhage and preparation method thereof | |
| Hongyu et al. | Advances in the pharmacological mechanism of Angelica sinensis in the treatment of ischemic stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120919 |